Insulet (NASDAQ:PODD) vs. Sintx Technologies (NASDAQ:SINT) Head-To-Head Survey

Sintx Technologies (NASDAQ:SINT) and Insulet (NASDAQ:PODD) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Institutional & Insider Ownership

18.4% of Sintx Technologies shares are held by institutional investors. 4.1% of Sintx Technologies shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Sintx Technologies and Insulet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-848.20%	-354.44%	-115.37%
Insulet	12.29%	29.29%	13.31%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sintx Technologies and Insulet, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1	0	3	0	2.50
Insulet	1	12	13	0	2.46

Sintx Technologies presently has a consensus price target of $9.50, suggesting a potential upside of 337.79%. Insulet has a consensus price target of $193.48, suggesting a potential upside of 44.00%. Given Sintx Technologies’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Sintx Technologies is more favorable than Insulet.

Earnings & Valuation

This table compares Sintx Technologies and Insulet”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02 million	9.19	-$10.36 million	($4.91)	-0.44
Insulet	$2.71 billion	3.44	$247.10 million	$5.35	25.11

Insulet has higher revenue and earnings than Sintx Technologies. Sintx Technologies is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Summary

Insulet beats Sintx Technologies on 8 of the 13 factors compared between the two stocks.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.